Genmab A/S is a leader in the creation and development of differentiated antibody products for the treatment of cancer, with headquarters in Copenhagen, Denmark. The construction of Genmab’s new headquarters will start in April 2021 and is expected to be ready in the first quarter of 2023. Genmab will lease the property for 15 years.

“I am very pleased that Genmab has chosen Kontorværket for its new headquarters. We expect the optimal infrastructure and fine architecture to bring in attractive companies. The agreement with Genmab is a confirmation of the promise for both the project and the location,” says Ole Faurby, Head of NCC Property Development Denmark.

“The new offices will house Genmab’s leading biotechnology experts in their important mission to transform cancer treatment. The future building will allow Genmab to work towards our mission and accommodate our workforce as we continue our growth trajectory,” says Birgitte Stephensen, SVP, IPR & Legal, Genmab site lead.

NCC will work in close cooperation with Genmab throughout the construction process. Kontorværket was designed by the award-winning DISSING+WEITLING architecture firm. The building will cover approximately 12,500 square meters. It also includes a basement covering 3,000 square meters and a parking garage next to the building, with space for 250 vehicles as well as bicycle parking facilities.

The building will receive a DGNB Gold sustainability certificate. DGNB is a global certification system, that offers a quality stamp of the property’s environmental standard, focusing on sustainability in relation to both social and economic aspects and climate impacts. Work is focused on material selection and resource consumption, lower energy costs and comfort in terms of air, temperature and acoustics.

The order was registered in the fourth quarter of 2020 in the Building Nordics business area.